- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Elinzanetant has Groundbreaking Impact on Hot Flashes and Quality of Life, suggests study
The nonhormonal drug elinzanetant showed substantial benefit for hot flashes, sleep disturbance, and quality of life in data from three randomized controlled trials presented at The Menopause Society 2024 Annual Meeting in Chicago. OASIS 1 and 2 trials were published in JAMA, and the OASIS 3 trial was presented as a poster at the conference. Recent research paper summarizes the findings from three randomized controlled trials (OASIS 1, 2, and 3) evaluating the efficacy and safety of the investigational drug elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Elinzanetant Mechanism and Trial Design
Elinzanetant is a selective neurokinin receptor antagonist that targets the estrogen-sensitive kisspeptin/NK B/dynorphin (KNDy) neurons, which are thought to play a role in thermoregulation and hot flashes during menopause. The OASIS 1 and 2 trials enrolled postmenopausal women aged 40-65 years with at least 50 moderate to severe vasomotor symptoms per week. They were randomized to receive either 120 mg of oral elinzanetant or placebo once daily for 12 weeks, after which the placebo group switched to elinzanetant for the final 14 weeks.
Findings from Elinzanetant Trials
The results showed that elinzanetant led to a significant reduction in the daily frequency and severity of vasomotor symptoms compared to placebo. Elinzanetant also significantly improved sleep disturbance and quality of life measures. The OASIS 3 trial, which assessed elinzanetant for 1 year, supported the findings from the earlier trials, demonstrating sustained efficacy over a longer duration.
Safety Considerations
Regarding safety, the most commonly reported adverse events with elinzanetant were headache, fatigue, and sleepiness. A higher proportion of elinzanetant users discontinued the study compared to placebo. However, there were no serious adverse events deemed treatment-related, and no evidence of endometrial hyperplasia, malignancy, or liver toxicity.
Potential Role of Elinzanetant
The authors suggest that elinzanetant may be a useful option for women who cannot or prefer not to use hormone therapy, including those with a history of estrogen-sensitive cancers, venous thromboembolism, or migraines with aura. The dual targeting of the NK-1 and NK-3 receptors by elinzanetant, in contrast to the NK-3 receptor-specific fezolinetant, may contribute to the broader improvements observed in vasomotor symptoms, sleep, and quality of life.
Key Points
1. The research paper summarizes the findings from three randomized controlled trials (OASIS 1, 2, and 3) evaluating the efficacy and safety of the investigational drug elinzanetant for the treatment of vasomotor symptoms associated with menopause.
2. Elinzanetant is a selective neurokinin receptor antagonist that targets the estrogen-sensitive kisspeptin/NK B/dynorphin (KNDy) neurons, which are thought to play a role in thermoregulation and hot flashes during menopause. The OASIS 1 and 2 trials enrolled postmenopausal women aged 40-65 years with at least 50 moderate to severe vasomotor symptoms per week, and randomized them to receive either 120 mg of oral elinzanetant or placebo once daily for 12 weeks, after which the placebo group switched to elinzanetant for the final 14 weeks.
3. The results showed that elinzanetant led to a significant reduction in the daily frequency and severity of vasomotor symptoms compared to placebo. Elinzanetant also significantly improved sleep disturbance and quality of life measures. The OASIS 3 trial, which assessed elinzanetant for 1 year, supported the findings from the earlier trials, demonstrating sustained efficacy over a longer duration.
4. Regarding safety, the most commonly reported adverse events with elinzanetant were headache, fatigue, and sleepiness. A higher proportion of elinzanetant users discontinued the study compared to placebo. However, there were no serious adverse events deemed treatment-related, and no evidence of endometrial hyperplasia, malignancy, or liver toxicity.
5. The authors suggest that elinzanetant may be a useful option for women who cannot or prefer not to use hormone therapy, including those with a history of estrogen-sensitive cancers, venous thromboembolism, or migraines with aura.
6. The dual targeting of the NK-1 and NK-3 receptors by elinzanetant, in contrast to the NK-3 receptor-specific fezolinetant, may contribute to the broader improvements observed in vasomotor symptoms, sleep, and quality of life.
Reference -
Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. Published online August 22, 2024. doi:10.1001/jama.2024.14618
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751